GlassScriptPhysician profile
Manaf Alroumoh
NPI 1548350614
$3,674.63
in general payments reported to CMS, 2019-2025
23 companies · $914 in 2025
The $914 reported for 2025 was more than what 76% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $185 · 2020: $219 · 2021: $496 · 2022: $642 · 2023: $461 · 2024: $758 · 2025: $914.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,982 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,982.18 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $836.36 | 2019-2025 | Jynarque, Voyxact |
| Astrazeneca Pharmaceuticals LP | $361.03 | 2021-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $356.37 | 2020-2023 | Veltassa |
| Travere Therapeutics, INC. | $317.14 | 2022-2025 | |
| Opko Pharmaceuticals, LLC | $284.85 | 2019-2025 | Rayaldee |
| Amgen INC. | $218.73 | 2019-2025 | Tavneos, Krystexxa |
| Fresenius USA Marketing, INC. | $184.16 | 2021-2025 | Nxstage System One, Velphoro, Velphoro |
| Novartis Pharmaceuticals Corporation | $169.58 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $161.64 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $145.13 | 2021-2024 | |
| Aurinia Pharma U.S., INC. | $130.99 | 2022-2025 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.96 | 2024-2025 | Jardiance |
| Lilly USA, LLC | $85.22 | 2023-2024 | Jardiance |
| Horizon Therapeutics Plc | $78.94 | 2021-2022 | |
| Ardelyx, INC. | $51.19 | 2024-2025 | Ibsrela |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $33.37 | 2025 | Empaveli |
| Akebia Therapeutics INC | $24.64 | 2025 | Auryxia, Vafseo |
| Ani Pharmaceuticals, INC. | $24.21 | 2024 | Purified Cortrophin Gel |
| Calliditas Therapeutics US INC. | $22.54 | 2022 | |
| Glaxosmithkline, LLC. | $22.22 | 2023 | Benlysta |
| Amicus Therapeutics, INC. | $21.10 | 2021 | |
| Cormedix INC. | $17.58 | 2025 | Defencath |
| Scpharmaceuticals INC. | $13.68 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manaf Alroumoh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.